Pleural Fluid Analysis: Standstill or a Work in Progress? by Hassan, T. et al.
Hindawi Publishing Corporation
Pulmonary Medicine
Volume 2012, Article ID 716235, 8 pages
doi:10.1155/2012/716235
Review Article
Pleural Fluid Analysis: Standstill or a Work in Progress?
T .H assan,M .Al -Al a wi,S.H.Ch o tirm all ,andN .G.M c El vaney
Respiratory Research Division, Educationand Research Center, Royal College of Surgeons in Ireland, Beaumont Hospital,
Beaumont Road, Dublin 9, Ireland
Correspondence should be addressed to S. H. Chotirmall, schotirmall@rcsi.ie
Received 5 September 2011; Accepted 26 October 2011
Academic Editor: Takashi Nakano
Copyright © 2012 T. Hassan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pleural ﬂuid analysis yields important diagnostic information in pleural eﬀusions in combination with clinical history,
examination, and radiology. For more than 30 years, the initial and most pragmatic step in this process is to determine whether
the ﬂuid is a transudate or an exudate. Light’s criteria remain the most robust in separating the transudate-exudate classiﬁcation
which dictates further investigations or management. Recent studies have led to the evaluation and implementation of a number
of additional ﬂuid analyses that may improve the diagnostic utility of this method. This paper discusses the current practice and
future direction of pleural ﬂuid analysis in determining the aetiology of a pleural eﬀusion. While this has been performed for a few
decades, a number of other pleural characteristics are becoming available suggesting that this diagnostic tool is indeed a work in
progress.
1.Introduction
Pleural eﬀusions are associated with a number of medical
conditions causing ﬂuid accumulation via diﬀering yet
synergistic mechanisms including increased pleural mem-
brane permeability, increased pulmonary capillary pressure,
decreased oncotic pleural pressure, and lymphatic obstruc-
tion. Pleural ﬂuid analysis yields important diagnostic infor-
mation in most cases of pleural eﬀusions. Standard workup
includes determining whether the eﬀusion is transudative or
exudative, an important diﬀerentiation aiding the physician
in narrowing the diﬀerential diagnosis (Figure 1). Despite
this, several experts propose that such a categorical division
represents outdated practice as it does not permit establish-
ing a deﬁnitive cause of the eﬀusion. A variety of nonroutine
tests may be performed during pleural ﬂuid analysis either
as lone or additional diagnostic tools to further determine
a deﬁnitive cause for an eﬀusion in the appropriate setting.
This paper will discuss the current practice and future
prospective direction for the use of pleural ﬂuid analysis in
determining the aetiology of a pleural eﬀusion in a variety of
clinical settings.
2. HaveWeMoved on from Light’s Criteria?
The primary aim when investigating a pleural eﬀusion is to
establish the correct diagnosis with minimal investigation.
Prior to the advent of Light’s criteria, most physicians
initially determined whether an eﬀusion was transudative or
exudative based on the pleural protein level [1]. Serum and
ﬂuid albumin gradients of greater than 12g/L also indicated
exudates, however, when used in isolation, these criteria have
low sensitivity [2].
Light’scriteriahaverecommendedforusewhenapleural
protein is between 25 and 35g/L and deﬁnes exudative pleu-
ral eﬀusions as having either (1) a ratio >0.5 between total
pleural and plasma protein, (2) a ratio >0.6 between pleural
and plasma lactate dehydrogenase (LDH), and (3) pleural
LDH higher than two thirds of the normal serum level.
The sensitivity of Light’s criteria in identifying exudative
pleuraleﬀusionsishigh(98%);however,itsabilitytoexclude
transudates remains low. For instance, prospective work by
Porcel et al. reported an almost 100% sensitivity for exudates
but found that approximately one-ﬁfth of patients with
congestivecardiacfailureondiureticsalsometLight’scriteria
for an exudate [3]. Despite this deﬁciency, Light’s criteria2 Pulmonary Medicine
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Figure 1: Recommended algorithm for investigation of pleural eﬀusion. The use of Light’s criteria is recommended when a thoracocentesis
revealed a protein level between 25 and 35g/L to narrow down the diﬀerential diagnosis by determining whether a pleural eﬀusion is
transudative or exudative. NT-proBNP should be measured when a suspected cardiac eﬀusion meets the exudative criteria. Determining
causes of an exudative eﬀusion is more challenging, and routine test, including biochemical measurement (i.e., pH and glucose), diﬀerential
cell counts, cytology, and routine microbiology test are diagnostically useful. Pleural ﬂuid pneumococcal antigen has been shown to be
superior than urinary antigen to identify bacterial-induced pleural eﬀusion. Tumour marker such as SMRP has a good diagnostic value
to diagnose mesothelioma, however, the diagnostic utility of other tumour markers remains limited. Immunocytochemical evaluation of
pleural ﬂuid specimen is helpful in labelling diﬀerent tumour markers. Other biological markers to diﬀerentiate parapneumonic/infective
and malignant eﬀusion remain elusive, expensive, and not widely available. Testing of pleural ﬂuid ADA is an inexpensive and eﬃcacious
method for diagnosing tuberculous eﬀusion, regardless of the patient’s immune status. Other tuberculosis-related inﬂammatory markers
are available but are not superior to the latter. (PF: pleural ﬂuid, black continuous line: strongly recommended and routinely practised, blue
continuous line: not strongly recommended and not routinely practised, red dotted line: complementary diagnosis with other nonpleural
tests.)
remain superior to clinical judgement for discriminating
between transudates and exudates. A prospective study of
n = 249 patients directly comparing clinical suspicion to
Light’s criteria reported that the former was signiﬁcantly
less accurate to the latter (84% versus 93%, P<0.01)
(6), illustrating the criteria’s importance in routine clinical
practice [4].
Most studies to date have focused on making Light’s
criteria more practical without aﬀecting its discriminatory
power.Forexample,ithasbeensuggestedthatserumLDHin
isolation does not increase the value of the two other criteria
components [5]. This is supported by a Brazilian study
proposing new criteria to diﬀerentiate the two eﬀusion types
[6]. By quantifying exclusively total pleural protein and LDH
without the need of serum samplings, this study showed a
diagnostic yield comparable to that of Light’s criteria.
Other studies have additionally generated a number of
nonroutine biochemical measurements on pleural ﬂuid that
may discriminate transudates from exudates, for instance
pleural ﬂuid bilirubin with pleural:serum ratio of >0.6 is
suggestive of an exudate with a sensitivity and speciﬁcity
of 90.6% and 96.2%, respectively [7]. An early case series
has demonstrated that pleural ﬂuid cholesterol >60mg/dL
is indicative of an exudative eﬀusion with high sensitivity
[8], whilst another study utilizing both LDH and pleural
cholesterol measurements revealed similar sensitivity toPulmonary Medicine 3
distinguish between the two types of eﬀusion [9]. Vascular
endothelial growth factor (VEGF), an important mediator of
angiogenesis and vascular permeability, may be another key
mediator and thus marker in the identiﬁcation of exudates
due to the increased pleural endothelial permeability it con-
fers. In one study of n = 79 patients, median levels of VEGF
in exudates were approximately twice that of transudates
[10].Inaddition,elevatedtumornecrosisfactoralpha(TNF-
α)l e v e l sa r ef o u n di nb o t hi n f e c t i o u sa n dm a l i g n a n tp l e u r a l
eﬀusions, but rarely transudates [11]. Other biochemical
parameters that have been examined to aid transudate
versus exudate diﬀerentiation include alkaline phosphatase,
creatine kinase, and uric acid which possessed diagnostic
accuracies lower than the traditional Light’s criteria [12].
Some of these studies have proposed new and alterna-
tive criteria avoiding venepuncture consequently reducing
investigations and diagnostic costs. However, these criteria
vary in their cut-oﬀ points to best discriminate the two
forms of eﬀusion. To date, Light’s criteria remain robust with
diagnostic accuracy of 96% and for now remains the optimal
method to separate pleural transudates from exudates.
3. CardiacPleuralEffusion: Extending
beyondthe Transudate/ExudateBoundary
Cardiac failure remains the most common cause of tran-
sudative pleural eﬀusions. A single study has revealed that
28% of cardiac-related pleural eﬀusions were misclassiﬁed as
exudative due to the use of diuretics [13]. Brain natriuretic
peptide (BNP) is a neuroendocrine hormone secreted from
the ventricular walls in response to increased pressures and
stretch conferred on cardiomyocytes impacting upon the
renin-angiotensin system to increase diuresis and vasodila-
tion [14]. BNP is cleaved to NT-proBNP, and detection of
the cleaved product in serum has been used to distinguish
cardiac failure from primary pulmonary causes of dyspnoea.
This marker has been demonstrated to possess diagnostic
usefulness during pleural ﬂuid analysis. A study by Long et
al. demonstrated that, although levels of pleural BNP have a
statistically signiﬁcant correlation with NT-proBNP, the lat-
ter is a far more accurate diagnostic tool during evaluation of
cardiac pleural eﬀusions [15]. In addition to high sensitivity
and speciﬁcity, pleural NT-proBNP is shown to be superior
to Light’s criteria for the identiﬁcation of cardiac-based
pleural eﬀusions [16]. Meta-analyses have shown that the
number of misclassiﬁed eﬀusions from application of Light’s
criteria wassigniﬁcantly reducedwith the use ofNT-proBNP
[17]. However, there is a need for caution as levels of NT-
proBNP are physiologically raised in the elderly and renal
failure populations requiring further studies to evaluate its
role in these groups. Importantly, NT-proBNP measurement
is diﬃcult and costly when compared to application of
traditional criteria such as the albumin gradient in assessing
pleuraleﬀusions[18].MeasuringpleuralNT-proBNPshould
therefore be reserved for settings where a suspected cardiac
eﬀusion meets exudative criteria but a high index of clinical
suspicion remains. Alternative markers have been studied
in the assessment of cardiac pleural eﬀusions, for example,
normal complement levels (C3 and C4) are reported to have
a high negative predictive value in this setting [19].
4. The Promiseof Biological Pleural
Markers to Determine the Aetiology of
Pleural Exudates
The most challenging aspect of investigating exudative pleu-
ral eﬀusions is diﬀerentiating the likelihood of inﬂammatory
parapneumonic versus malignant disease both major causes
ofexudatesinroutineclinicalpractice.Tuberculouseﬀusions
are an additional important consideration owing to long-
term treatment strategies. Biochemical analyses such as pro-
tein, pH, and microbiologic assessment remain the standard
investigations during this process. Additionally, cytological
examination of suspected malignant pleural eﬀusion (MPE)
can result in false-negative rates of up to 40% [20]. The
diagnostic yield for cytology, however, depends on the
tumour type; highest for ovarian (83%) and less so for breast
(78%), lung (57%), and mesothelioma (41%) primaries.
Overall, standard testing to determine the underlying cause
of exudates has a suboptimal accuracy requiring other
parameters such as clinical suspicion and radiology to play
an associative role.
4.1. Pleural Fluid Appearance. Pleural ﬂuid appearance is
a nonspeciﬁc and undermined tool in the assessment of a
pleural eﬀusion. Prior work has suggested that malignancy
is the leading cause of gross bloody eﬀusions (47%) [21]
and further conﬁrmed by Porcel and Vives who reported
that pleural eﬀusions with signiﬁcantly higher red blood cell
counts occurred in those who subsequently had malignant
rather than nonmalignant eﬀusions [22]. In a separate study
assessing patients without any prior diagnosis of malignancy,
an association between blood-stained eﬀusions and the
presence of malignant cells on cytological examination
was described [23]. Conversely, a larger retrospective study
assessing patients diagnosed with cancer who underwent
thoracocentesis revealed no diﬀerence between the presence
ofbloodandtheabilitytopredictpositivepleuralﬂuidcytol-
ogy [24]. Therefore, due to low sensitivity and speciﬁcity of
bloody eﬀusions to indicate malignancy in the setting of an
exudate, pleural ﬂuid appearance should not be emphasized
as a diagnostic tool to establish MPE as it can be relatively
nonspeciﬁc.
On the other hand, there are cases where the appearance
of pleural ﬂuid may be helpful. The best described setting
is one of a milky appearance suggestive of chylothorax or
pseudochylothorax that can be diﬀerentiated by centrifuga-
tion. Although reliable where present, the gross appearance
of a chylothorax has been described as nonmilky half the
time[25].Chylothoraxmayalternativelygivetheappearance
of bile-stained ﬂuid. However, pleural triglyceride analysis
is a more deﬁnitive test with a level greater than 110mg/dL
reﬂecting a 99% chance that the ﬂuid is chyle. For infective-
related pleural eﬀusions, an anchovy-brown ﬂuid may
indicate amoebic liver abscess whilst black ﬂuid suggests
Aspergillus infection [26].4 Pulmonary Medicine
4.2. Cell Count Diﬀerential. Diﬀerential cell count of pleural
ﬂuid may also provide clues to the origin of an exudative
pleural eﬀusion. Neutrophilic predominance indicates an
acute injury of the pleural surface that may occur in
parapneumonic settings, pulmonary embolism, and sub-
phrenic abscesses. In chronic, long standing pleural injury,
the ﬂuid becomes populated by lymphocytes. Two-thirds
of lymphocytic predominant eﬀusions are the result of
malignancy or tuberculosis (TB) [27]. Eosinophilic pleural
eﬀusions, deﬁned as a pleural eﬀusion that contains at least
10% eosinophils, most commonly occur during conditions
associated with the presence of blood or air in the pleural
space such as pneumothorax and malignancy. Interestingly,
although eosinophilia is nonspeciﬁc and can occur in
benign-related eﬀusions, a percentage of pleural eosinophils
>40% indicates an extremely low likelihood of malignancy
[28].
4.3. Markers of Pleural Inﬂammation. Pleural biological
markers have been proposed as an alternative means to
determinethecauseofexudativepleuraleﬀusions.C-reactive
protein is an acute-phase reactant widely used as a marker of
inﬂammation and tissue injury. Pleural CRP is found to be
higher in benign versus malignant exudates with a sensitivity
and speciﬁcity of 93.7% and 76.5% for parapneumonic
eﬀusion [29, 30]. This ﬁnding has been supported by further
studies revealing an almost 100% sensitivity for a cut-
oﬀ value of 5.3mg/dL to identify parapneumonic versus
tuberculous or malignant eﬀusions [31]. Interleukin-8 (IL-
8), a proinﬂammatory cytokine, and CRP together may
diﬀerentiate complicated from uncomplicated parapneu-
monic eﬀusions with sensitivities of 84% and 72% and
speciﬁcities of 82% and 71%, respectively [32]. Interleukin-6
(IL-6), an alternative proinﬂammatory cytokine induced by
lipopolysaccharide (LPS) as a marker of system activation,
has also been shown to eﬀectively diﬀerentiate infective
from malignant eﬀusions with highest levels in tuberculous
rather than parapneumonic eﬀusions [33]. In spite of this,
elevated IL-6 has also been found in MPE, particularly
following pleurodesis. Elevated TNF-α is also useful in
diﬀerentiating tuberculous from malignant eﬀusions [34].
Studies supporting the utility of pleural proinﬂammatory
cytokines during pleural ﬂuid analysis revealed that a low
absolute neutrophil count may give a diagnosis of empyema
withasensitivity rateof 78.6%andaspeciﬁcity rateof88.4%
in the presenceof elevated IL-8. Similar ﬁndings arereported
with IL-1 [35, 36].
Other features of pleural ﬂuid analysis that discriminate
infection from inﬂammation in the complicated versus
noncomplicated setting include pleural soluble triggering
receptor of myeloid cells-1 (sTREM-1), procalcitonin, and
lipopolysaccharide binding protein (LBP) [37]. Pleural
pneumococcal antigen assays have been explored and may
be more sensitive than the equivalent urinary assays for
the establishment of microbial-induced pneumonias [38].
Parapneumonic eﬀusions secondary due to S. pneumoniae
are further shown to have positive antigen testing in pleural
ﬂuid whilst negative results from concurrent urine sampling.
A prospective study of n = 72 patients set out to discrim-
inate exudates with multiple pleural biological parameters
including adenosine deaminase (ADA), CRP, carcinoem-
bryogenic antigen (CEA), IL-6, TNF-α, and VEGF found
ADA and CRP to be the most reliable of the group assessed
[39]. ADA concentrations >45U/L and CRP <4mg/dLmost
likely indicated tuberculous eﬀusions, whilst ADA <40U/L
and CRP >6mg/dL suggested a parapneumonic origin. The
latter ADA levels in combination with CRP <4mg/dL on
the other hand, were most likely malignant in origin. In a
specialized subgroup of lung transplant recipients, normal
or high complement levels within pleural ﬂuid indicate
a secondary cause, for example, parapneumonic eﬀusion
rather than those attributable to the surgery itself [19].
Despite the large volume of work in-progress, larger and
more robust studies are necessitated before we can safely
recommend the use of nonroutine and costly biological
markers as standard to improve the diagnostic accuracy
during the routine workup of an exudative pleural eﬀusion.
4.4. Pleural Tuberculosis. Pleural tuberculosis displays im-
portant pleural ﬂuid features that signiﬁcantly contribute to
the diagnostic process. Such features preclude the need for
invasive investigation such as thoracoscopy or pleural biopsy.
Microbiologic assessment remains paramount directly aid-
ing treatment strategy. Microscopic examination of Ziehl-
Neelson stained pleural ﬂuid detects acid-fast bacilli in
<5% of non-HIV cases [40]. Addition of Lowenstein-Jensen
media culture increases this positive yield to approximately
35%. Nucleic acid ampliﬁcation confers better statistics
for diagnosis and has speciﬁcity between 90%, and –97%;
however, sensitivity may be as low as 60% [41].
ADA is a T-cell (CD4+) metalloenzyme whose presence
in high levels within pleural ﬂuid strongly indicated tubercu-
losis particularly in high prevalence areas. High pleural ADA
is also detected in non-TB settings including malignancy,
rheumatoid arthritis, systemic lupus erythematosis, and
parapneumonic eﬀusions. In view of this, it is important to
acknowledge that two ADA isoenzymes exist; ADA 1 and 2
with the latter related in increased levels in the tuberculous
setting. In meta-analyses of 63 studies, ADA is reported to
have a sensitivity of 92% and a speciﬁcity of 90% [42], whilst
within the setting of a lymphocytic predominant eﬀusion,
ADA >40U/L is almost exclusively secondary to tuber-
culosis. Paradoxically, retrospective study of 221 patients
has illustrated that ADA levels >250U/L do not generally
occur in tuberculosis related eﬀusions [43]. Such levels
are in fact found in patients with empyema or lymphoid-
related malignancies. Therefore, whilst the measurement
of pleural ﬂuid ADA remains a useful diagnostic tool for
tuberculous pleurisy, it should be interpreted in parallel with
clinical ﬁndings and other traditional methods such as the
tuberculin skin test to reach a diagnosis. Such a combination
of clinical features with pleural ADA measurement has
excellent diagnostic value with a sensitivity and speciﬁcity
rates of 95% and 97%, respectively. Therefore, experts have
recommendedmeasuringADAlevelsinlow-prevalenceareas
as a concentration <40U/L almost exclusively rules out
tuberculosis-driven eﬀusions [44].Pulmonary Medicine 5
Measurement of pleural interferon-γ,a na l t e r n a t i v e
cytokine derived from lymphocytes, may also be utilized in
the diagnosis of tuberculous eﬀusions. However, like ADA,
elevated levels of interferon-γ are reported in empyema
and malignancy. Even though the sensitivity and speci-
ﬁcity of this marker is lower than that of ADA, joint
sensitivity and speciﬁcity utilizing both together increases
to 96% and 93%, respectively [45]. A single prospective
study of n = 63 patients illustrated that interferon-γ
gamma assays (IGRAs) including the commercially available
QuantiFERON-TB Gold and T-SPOT-TB performed poorly
compared to interferon-γ levels >0.31IU/mL as a cut-oﬀ
value [46]. Use of IGRA is currently not recommended due
tovariabilityinresultswhencomparedtoothermarkerssuch
as ADA that appear superior.
Other biological parameters including pleural IL-6, IL-
1β, neopterin, leptin, lysozyme, and soluble FAS ligand have
extensively been studied in the setting of tuberculous pleural
eﬀusions. Neopterin is a pteridine, released by activated
macrophages and shown to be elevated in tuberculous eﬀu-
sions [47]. Conversely, leptin, an adipose-derived hormone,
has been shown to be reduced to a greater extent in tubercu-
lous eﬀusions when compared to other exudative eﬀusions
with a sensitivity and speciﬁcity of 82% [48]. Lysozyme
also released from activated macrophages similarly have a
sensitivity of 85% and speciﬁcity 61% for the identiﬁcation
of tuberculous eﬀusions. SC5b-9, a product derived from the
binding of C5b-9 complexes to the S protein, is elevated in
eﬀusions secondary to TB particularly at a cut-oﬀ value of
>2mg/L. Such measurements have also been studied to aid
diﬀerentiating tuberculous from malignant pleural eﬀusions
[49]. Pleural interferon-γ inducible 10k-Da protein (IP-10),
interleukin-12p40, and matrix metalloproteinase (MMP)
levels [50–52] are additional markers elevated in pleural
ﬂuid from tuberculous eﬀusions compared with malignant
and other benign settings. Despite this, their signiﬁcant
variability in sensitivity and speciﬁcity coupled with costs for
routine use preclude the introduction of such measures into
routine clinical practice. What is probably most feasible is a
combination of these tests used synergistically at a reduced
cost. For example, a study has shown that a combination
assay including ADA, interferon-γ, and nucleic acid ampli-
ﬁcation for TB will have superior sensitivity and speciﬁcity
as compared to a single test alone and oﬀers a future promise
in the workup of tuberculous eﬀusions [53].
4.5.TumourMarkers. Nodularity,pleuralanddiaphragmatic
thickening are highly indicative of malignant pleural disease
with a positive predictive value of 100%. Despite this, such
featuresarenotalwayspresentandpleuralﬂuidcytologythus
plays a crucial role in the diagnosis of malignancy. MPEs are
positive in 40–60% of cases [54] ,a n di ti sc o m m o np r a c t i c e
to require a large volume (>500mLs) of ﬂuid to reach
a diagnosis by cytology. Interestingly, a recent prospective
study on n = 121 thoracocentesis showed that diagnostic
accuracy was dependent on the volume of pleural ﬂuid
obtainedwitharecommendationof>150mL,whilstanother
prospective study examining n = 44 patients concluded that
samples >50mL similarly did not increase diagnostic yields
[55, 56]. Work on noninvasive tumour biomarkers remain
ongoing and if successful may avoid invasive investigation
such as pleural biopsy or thoracoscopy.
Well-described tumour markers such as carcinoembry-
onic antigen (CEA), cancer antigen 125 (CA 125), 15-3
(CA 15-3), and neuron-speciﬁc enolase/cytokine fragment
(CYFRA) 21-1 have limited usefulness in the routine workup
of a suspected malignant pleural eﬀusion. CA 125 is a well-
d e s c r i b e dt u m o u rm a r k e ri m p l i c a t e di no v a r i a nm a l i g n a n c y
and has reported high levels in pleural ﬂuid compared to
serum in this setting [57]. High pleural CA 125, however, is
also observed in squamous and adenocarcinomatous malig-
nant eﬀusions and may have a prognostic role [58]. Pleural
C E Aw a so n eo ft h eﬁ r s tm a r k e r st ob ee v a l u a t e di nl u n g
cancer. It is overexpressed in metastatic adenocarcinoma
possessing prognostic relevance in terms of median survival
and treatment response [59]. Although CEA has been shown
to be speciﬁc, sensitivity remains low (<50%) with variable
cut-oﬀ values precluding routine use. Metastatic breast can-
cer is another common cause for malignant pleural eﬀusions
with CA 15-3 used for both diagnosis and therapeutic
monitoring [60]. CYFRA 21-1, a cytokeratin tumour marker
has both diagnostic and prognostic roles in nonsmall cell
lung cancer [60]. However, due to relatively poor sensitivity
for a single test, use of a combination of tumour markers
such as CA 125 and CYFRA 21-1 for adenocarcinoma and
CEA, CA 15-3, and CYFRA 21-1 for squamous cell cancer
of the lung has been recommended. In a study involving
n = 243 and n = 173 patients with malignant and
benign eﬀusions, respectively, selected cut-oﬀ values had to
be 100% speciﬁc to classify correctly 54% of the malignant
eﬀusions [61]. Discriminating pleural ﬂuid cut-oﬀ values
were generally higher than those found in serum, a ﬁnding
that does not justify the routine use of measuring classic
tumour markers in the workup of pleural eﬀusions. Despite
this, one particular study has in fact demonstrated that in
cases of suspicious MPE and negative cytology and in the
absence of an obvious primary source that the measurement
of tumour markers may be helpful as an alternate diagnostic
tool [62].
The diagnosis of a mesothelioma-related pleural eﬀusion
remains diﬃcult as few studies have reported markers
with a high positive predictive value. Increased levels of
pleural CA-15-3, hyaluronic acid, and spliced forms of
CD44, such as exon v6 (CD44v6), have been reported;
however, a discrepancy exists in the literature for CYFRA 21-
1t od i ﬀerentiate between mesothelioma and other pleural
malignancies [63]. Alternatively, mesothelin, a cell surface
glycoprotein that may be cleaved into the soluble mesothelin
related protein (SMRP), is a moderately sensitive but highly
speciﬁc marker in serum studies [64]. Studies also support
the use of pleural ﬂuid levels of mesothelin with 98%
speciﬁcity and 67% sensitivity in mesothelioma compared
to benign eﬀusions [65, 66]. Pleural SMRP measurement
also diagnosed mesothelioma more reliably than cytological
examination alone [65, 67]. Consequently, such a measure
could be considered for patients with undiagnosed pleural
eﬀusions, particularly if mesothelioma is a concern.6 Pulmonary Medicine
Immunocytochemistry may also be performed on cyto-
logical pleural ﬂuid specimens. For example, several mes-
othelial markers such as calretinin, keratin 5/6, and WT-1
protein may be used in conjunction with carcinoma markers
such as thyroid transcription factor-1 (TTF-1), CEA, and
B72.3. These may be used to eﬀectively discriminate epithe-
lial mesothelioma from adenocarcinoma [68]. Whilst 80%
of lung adenocarcinoma exhibits TTF-1 positivity, a positive
TTF-1 stain in pleural ﬂuid without an established primary
cause may alternatively suggest primary non-small cell lung
cancer[68].Inthesettingofbreastmalignancy,useofpleural
Her-2-neu receptor positivity has diagnostic and therapeutic
implications [69]. Although useful in particular settings, the
weaknesses associated with the routine use of measuring
tumour biomarkers in pleural ﬂuid should be recognized by
clinicians.
4.6. Rheumatological-Related Pleural Eﬀusions. Rheumato-
logical-related pleural eﬀusions usually have pleural bio-
chemical characteristics such as protein, pH, and glucose
similar to other noninfective causes of exudates. Serum
rheumatoid factor (RF) and antinuclear antibody (ANA) are
more sensitive and speciﬁc for the diagnosis of rheumatoid
arthritis (RA) and systematic lupus erythematosis (SLE);
however, their measurement in pleural ﬂuid does not possess
the same diagnostic accuracy for disease-related pleural
eﬀusions. RF titres may be measured in pleural ﬂuid and are
often >1:320 in rheumatoid pleuritis. Despite this ﬁnding,
this measurement is rarely practiced in the clinical setting as
the pleural levels often reﬂect serum values. One particular
study conﬁrmed this fact as it reported no additional diag-
nostic value above that of serum analysis alone [70]. Cyto-
logical assessment looking for “ragocyte” cells that consist
of white blood cells with phagocytic intracellular inclusions
is described in rheumatoid pleuritis but generally has low
speciﬁcity. Pleural ANA is additionally not speciﬁc to SLE
and may occur in malignancies. Interestingly, however, one
studyhassuggestedthatpleuralANAmeasurementpossesses
good negative predictive value for SLE pleuritis and may be
useful in this context [71]. Conversely, an alternative study of
n = 266patientshasshownnoadditionalvalueinmeasuring
pleural ANA in the setting of SLE pleuritis [72]. Pleural anti-
double stranded DNA (dsDNA) also has good negative pre-
dictivevalue,whilstcomplementactivationofpleuralﬂuidin
both RA and SLE has also been evaluated but is not routinely
practiced in the clinical setting due to its low speciﬁcity [73].
5. Conclusion
Since the introduction of Light’s criteria in the 1970s,
other proposed criteria and recommendations to overcome
some of its drawbacks have been suggested, however, Light’s
criteria have remained biochemically the most robust for
diﬀerentiating exudates from transudates. This allows easier
diagnosis for an underlying cause of a pleural eﬀusion,
avoiding unnecessary investigation. Nevertheless, most tran-
sudates are in fact secondary to congestive heart failure
where clinical judgement and disease-speciﬁc markers such
asNT-proBNP havebeenproventobesuperior.Otheruseful
disease-speciﬁc markers include ADA in the diagnosis of
tuberculous eﬀusions. Discriminating malignant and benign
pleural eﬀusions in the setting of an exudate remains a
challenge. While there is no substitute to the histologic
demonstration of malignancy, the role of tumour markers
may emerge to have a larger contribution in the future as a
complementary tool in the setting of MPE particularly when
considering the invasiveness and lack of universal accessibil-
ity to thoracoscopy. Although workup of pleural eﬀusions
is a mix of both old and new measures, novel technologies
such as global gene proﬁling and proteomics enable the
identiﬁcation of “ﬁngerprints” for disease-speciﬁc markers
that will undoubtedly improve our approach in the diagnosis
for a deﬁnitive cause of a particular pleural eﬀusion. Such
future improvements do illustrate major advances from the
simplistic transudate-exudate separation and do suggest that
pleural ﬂuid analysis is in fact a work in progress.
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